Journal Paper

Paper Information

Journal:
Year:0 | Volume: | Issue:
Start Page: | End Page:

video

sound

Persian Version

View:

23,001

Download:

16,236

Cites:

Information Journal Paper

Title

EVALUATION OF PROMOTER HYPERMETHYLATION OF TUMOR-SUPPRESSOR GENES P14 AND P16 IN IRANIAN ENDOMETRIAL CARCINOMA PATIENTS

Pages

 Start Page 179 | End Page 186

Abstract

 Background: ENDOMETRIAL CANCER is a common gynecological malignancy with good prognosis in the early stages of the disease. The CpG island in the promoter region of tumor-suppressor genes are frequently methylated in various types of human cancers. In the present study, we have examined the methylation status of thep16INK4a and P14ARFgenes in ENDOMETRIAL CANCER and healthy endometrium with the aim to identify correlations between promoter hyper methylation, disease risk, and clinic opathological parameters.Methods: We collected 28 formalin fixed paraffin embedded samples and 26 blood samples from ENDOMETRIAL CANCER patients and 22 controls. Methylation-specific PCR was applied to analyze the promoter methylation status of thep16INK4a and P14ARFgenes in the studied population. The results were analyzed with SPSS software version 20.Results: There was a significant difference between the study groups and the presence of promoter CpG hyper methylation status in thep14 (P<0.0001) and p16 (P<0.05) genes. p14 hyper methylation in the blood samples was associated with depth of myometrial invasion in ENDOMETRIAL CANCER (P=0.03). A significant association existed betweenp16 methylation in tissue with ENDOMETRIAL CANCER grade (P=0.06). No statistically significant difference existed between thep16INK4a and P14ARF promoter hyper methylations in blood (P=0.177) and formalin fixed paraffin embedded (P=0.221) samples. An association existed betweenp16INK4a and P14ARF gene hyper methylations in blood and tissue with diabetes.Conclusion: Our results have confirmed that EPIGENETIC mechanisms play an important role in ENDOMETRIAL CANCER incidence. They can be utilized as prognostic biomarkers for ENDOMETRIAL CANCER. The lack of a significant difference between the P16INK4A and P14ARF promoter hyper methylations in blood and formalin fixed paraffin embedded samples has indicated that methylation status of a blood sample can be an early, non-invasive diagnostic marker in ENDOMETRIAL CANCER.

Cites

  • No record.
  • References

  • No record.
  • Related Journal Papers

  • No record.
  • Related Seminar Papers

  • No record.
  • Related Plans

  • No record.
  • Recommended Workshops